Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1641 1644 1647
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17763116 | RECEPTORS WITH HETEROLOGOUS TRANSMEMBRANE DOMAIN | Final Rejection | The Regents of the University of California |
| 17513710 | PURIFICATION PLATFORMS FOR OBTAINING PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED HYDROLYTIC ENZYME ACTIVITY RATE | Non-Final OA | Genentech, Inc. |
| 18367252 | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF | Non-Final OA | Bristol-Myers Squibb Company |
| 18314339 | ANTI-TL1A ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Bristol-Myers Squibb Company |
| 17439124 | CYTOKINE-BASED IMMUNE CELLS AND IMMUNOTHERAPEUTIC USE THEREOF | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17777363 | COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY | Final Rejection | University of Massachusetts |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | Non-Final OA | City of Hope |
| 17918644 | CHIMERIC MYD88 RECEPTORS | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 17674991 | HORSE IL-31 INDUCED PRURITUS MODEL | Non-Final OA | Zoetis Services LLC |
| 18027338 | BATF AND IRF4 IN T CELLS AND CANCER IMMUNOTHERAPY | Non-Final OA | LA JOLLA INSTITUTE FOR IMMUNOLOGY |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | Juno Therapeutics, Inc. |
| 18000468 | ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 17921378 | BISPECIFIC ANTIBODY TARGETING HUMAN CLAUDIN AND HUMAN PDL1 PROTEINS, AND APPLICATION THEREOF | Non-Final OA | QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. |
| 18250165 | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF IN THE TREATMENT OF OCULAR MELANOMA | Non-Final OA | PURETECH LYT, INC. |
| 17613020 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Final Rejection | LES LABORATOIRES SERVIER |
| 18172928 | ANTIBODY MOLECULES THAT BIND TO NKP30 AND USES THEREOF | Non-Final OA | Marengo Therapeutics, Inc. |
| 18018711 | ANTI-TIM3 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARING MEDICINE FOR TREATING TUMOR | Final Rejection | Beijing Neurosurgical Institute |
| 17793771 | ENHANCED RECEPTOR FOR IMPROVING IMMUNE CELL FUNCTION | Final Rejection | CHINEO MEDICAL TECHNOLOGY CO., LTD. |
| 18005669 | COMPOSITIONS AND METHODS TO TARGET ANTI-TNF-ALPHA ANTIBODY | Non-Final OA | PORTON BIOLOGICS LTD |
| 18016203 | NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF | Non-Final OA | NANJING BIOHENG BIOTECH CO., LTD |
| 18008581 | CD38 antibodies for the treatment of human diseases | Non-Final OA | Y-mAbs Therapeutics, Inc. |
| 17764854 | IgE Antibody with FcRn binding | Final Rejection | Epsilogen Ltd |
| 17641594 | IMMUNOTHERAPY COMPOUNDS AND METHODS | Final Rejection | GT BIOPHARMA, INC. |
| 16956510 | COMBINATION ANTI CANCER THERAPY WITH AN IAP ANTAGONIST AND AN ANTI PD-1 MOLECULE | Final Rejection | Debiopharm International S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy